Search
Now showing items 11-19 of 19
Glycogen-rich Clear Cell Carcinoma of the Breast: A Comprehensive Review.
(
Lippincott, Williams & Wilkins
, 2020 , Article Review)
Glycogen-rich clear cell carcinoma (GRCC) is a very rare form of primary breast cancer (<0.1% of all breast cancers). It is characterized by the presence of neoplastic cells with a glycogen-abundant clear cytoplasm (the ...
Molecular Profiling Reveals Limited Targetable Biomarkers in Neuroendocrine Carcinoma of the Cervix.
(
Lippincott, Williams & Wilkins
, 2020 , Article)
Neuroendocrine carcinoma of the cervix (NEC) is a rare and highly aggressive cervical malignancy. Given that no targeted therapy has been approved specifically to NEC, we investigated the presence of novel, potentially ...
TERT gene fusions characterize a subset of metastatic Leydig cell tumors
(
Elsevier
, 2021 , Article)
Objective: Metastatic Leydig cell tumors (LCT) are rare, difficult to treat malignancies without known underlying molecular-genetic events. An index case of metastatic LCT showed an LDLR-TERT gene fusion upon routine genetic ...
The Role of Pathology in the Era of Personalized (Precision) Medicine: A Brief Review.
(
NLM (Medline)
, 2021 , Article)
This review provides a brief overview of the state-of-the-art molecular pathology approaches emphasizing the increasingly important pathology role in clinical precision cancer medicine. Recent advances in molecular biology ...
Nutm1-rearranged neoplasms: A heterogeneous group of primitive tumors with expanding spectrum of histology and molecular alterations: An updated review
(
MDPI
, 2021 , Article)
Nuclear protein of testis (NUT), a protein product of the NUTM1 gene (located on the long arm of chromosome 15) with highly restricted physiologic expression in post-meiotic spermatids, is the oncogenic driver of a group ...
Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy
(
Elsevier Ltd
, 2018 , Article)
Background: Cancer of unknown primary (CUP) accounts for approximately 3% of all malignancies. Avoiding immune destruction is a major cancer characteristic and therapies aimed at immune checkpoint blockade are in use for ...
PD-L1 testing by immunohistochemistry in Immuno-Oncology.
(
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
, 2022 , Article Review)
Immunotherapy, based on immune checkpoint inhibitors targeting the Programmed cell death ligand 1 (PD-L1) and/or Programmed Death Receptor 1 (PD-1), has substantially improved the outcomes of patients with various cancers. ...
Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group
(
Academy of Sciences and Arts of Bosnia and Herzegovina
, 2022 , Article)
In the present review, we briefly discuss the breakthrough advances in precision medicine using a tumor-agnostic approach and focus on BRAF treatment modalities, the mechanisms of resistance and the diagnostic approach in ...
An Updated Review of the Biomarkers of Response to Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: Merkel Cell Carcinoma and Immunotherapy
(
Multidisciplinary Digital Publishing Institute (MDPI)
, 2023 , Article)
Merkel cell carcinoma (MCC) is primarily a disease of the elderly Caucasian, with most cases occurring in individuals over 50. Immune checkpoint inhibitors (ICI) treatment has shown promising results in MCC patients. ...